Navigation

Hepatitis C (genotype 1) - boceprevir [ID460]

Boceprevir for the treatment of genotype 1 chronic hepatitis C

Status: History
Expected date of issue: April 2012
Referral date: May 2011
Process: STA
Notes:

Scoped within Batch 17

Topic area:
  • Digestive system
  • Infectious diseases
 

NICE project team

Executive Lead: Gillian Leng
Technical Lead: Linda Landells
Communications manager: Philip Ranson
Project manager: Kate Moore
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 2 August 2011
1st appraisal committee meeting: 24 January 2012
Top


 

Consultees and commentators

Consultees Commentators (no right to submit or appeal)

Manufacturers/sponsors

  • Merck Sharp and Dohme (boceprevir)

Patient/carer groups

  • British Liver Trust
  • Hepatitis C Trust

Professional groups

  • British Association for the Study of the Liver
  • British Society of Gastroenterology
  • Royal College of Nursing
  • Royal College of Pathologists
  • Royal College of Physicians

Others

  • Department of Health
  • Welsh Government

General

  • British National Formulary
  • Commissioning Support Appraisals Service
  • Department of Health, Social Services and Public Safety for Northern Ireland
  • Healthcare Improvement Scotland

Possible comparator manufacturer(s)

  • Janssen (telaprevir)
  • Roche Products (peginterferon alfa, ribavirin)
  • Merck Sharp and Dohme (peginterferon alfa, ribavirin)

Relevant research groups

  • Foundation for Liver Research

Evidence Review Groups

  • Southampton Health Technology Assessment Centre (SHTAC), University of Southampton
  • National Institute for Health Research Health Technology Assessment Programme

Associated guideline groups

  • National Clinical Guidelines Centre

Associated public health groups

  • None

Top


 

Project history

Date Update
8 December 2011

Following the cancellation of our November committee meeting, we are now able to confirm the new date for the first committee meeting for this appraisal.

The first discussion of this topic will be at our committee meeting on 24 January 2012

22 November 2011

Due to illness of the Committee chair, the Appraisal Committee meeting on 23 November 2011 to discuss Boceprevir for the treatment of genotype 1 chronic hepatitis C has been cancelled. All alternative options were explored; however, we were unable to control for this situation.

The topics planned to be discussed at this meeting will be re-scheduled into the work programme. We will update here as soon as further details are available.

Top


 

Key documents

This page was last updated: 17 May 2012

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.